Dosing Practices and Risk Factors for Bleeding in Patients Receiving Enoxaparin for the Treatment of an Acute Coronary Syndrome

This publication has 26 references indexed in Scilit:

• ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction—2002: Summary Article
  Circulation, 2002
• Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis
  The Lancet, 2000
• Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome)
  Published by Oxford University Press (OUP) ,1999
• Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non–Q-Wave Myocardial Infarction
  Circulation, 1999
• Low-Molecular-Weight Heparins
  New England Journal of Medicine, 1997
• A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease
  New England Journal of Medicine, 1997
• Comparison of Low-Molecular-Weight Heparin With Unfractionated Heparin Acutely and With Placebo for 6 Weeks in the Management of Unstable Coronary Artery Disease
  Circulation, 1997
• Delayed elimination of enoxaparine in patients with chronic renal insufficiency
  Thrombosis Research, 1991
• ABSENCE OF ABDOMINAL PAIN IN ELDERLY PATIENTS WITH PEPTIC ULCER
  Age and Ageing, 1984
• Prediction of Creatinine Clearance from Serum Creatinine
  Nephron, 1976